11/18/2025

Janusmed kön och genus

Janusmed kön och genus – Mounjaro KwikPen

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Tirzepatid

Tirzepatid

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Carlsson S, Andersson T, Jansson S, Nyström T, Rolandsson O, Wei Y. Increasing incidence of early-onset type 2 diabetes in Sweden 2006-2021. Eur J Public Health. 2025;:.

  2. Folkhälsomyndigheten. Övervikt och obesitas, interaktivt faktablad. Folkhälsomyndigheten [www]. [updated 2025-03-17, cited 2025-10-24].

  3. Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment. Curr Obes Rep. 2021;10(4):458-466.

  4. Censin JC, Peters SAE, Bovijn J, Ferreira T, Pulit SL, Mägi R et al. Causal relationships between obesity and the leading causes of death in women and men. PLoS Genet. 2019;15(10):e1008405.

  5. Statistikdatabas för operationer. Stockholm: Socialstyrelsen. 2024 [cited 2025-10-24.]

  6. Assessment report - Mounjaro (tirzepatide). European Medicines Agency (EMA) [www]. [updated 2022-07-21, cited 2025-10-24].

  7. De Block C, Peleshok J, Wilding JPH, Kwan AYM, Rasouli N, Maldonado JM et al. Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. Diabetes Ther. 2025;16(1):43-71.

  8. Plat AW, Rasouli N, Peleshok J, Sapin H, Wilding J. Change in Body Weight from Baseline with Tirzepatide: Sex Subgroup Analysis of the SURPASS Studies. Diabetes 2022;71 (supplement_1):720-P.

  9. Małecki MT, Batterham RL, Sattar N, Levine JA, Rodríguez Á, Bergman BK et al. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4. Diabetes Care. 2023;46(12):2292-2299.

  10. Garcia LE, Chao A, Mojdami D, Forrester T, Taylor R, Chigusta F et al. Body weight reduction with tirzepatide by sex: a subgroup analysis of the SURMOUNT clinical trials (abstract). EASD Annual Meeting [cited 2025-10-28]

  11. Ou Y, Cui Z, Lou S, Zhu C, Chen J, Zhou L et al. Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups. Front Pharmacol. 2024;15:1463657.

  12. Mounjaro (tirzepatide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-01-11, cited 2025-10-28]

  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Carlsson S, Andersson T, Jansson S, Nyström T, Rolandsson O, Wei Y. Increasing incidence of early-onset type 2 diabetes in Sweden 2006-2021. Eur J Public Health. 2025;:.
  2. Folkhälsomyndigheten. Övervikt och obesitas, interaktivt faktablad. Folkhälsomyndigheten [www]. [updated 2025-03-17, cited 2025-10-24].
  3. Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment. Curr Obes Rep. 2021;10(4):458-466.
  4. Censin JC, Peters SAE, Bovijn J, Ferreira T, Pulit SL, Mägi R et al. Causal relationships between obesity and the leading causes of death in women and men. PLoS Genet. 2019;15(10):e1008405.
  5. Statistikdatabas för operationer. Stockholm: Socialstyrelsen. 2024 [cited 2025-10-24.]
  6. Assessment report - Mounjaro (tirzepatide). European Medicines Agency (EMA) [www]. [updated 2022-07-21, cited 2025-10-24].
  7. De Block C, Peleshok J, Wilding JPH, Kwan AYM, Rasouli N, Maldonado JM et al. Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. Diabetes Ther. 2025;16(1):43-71.
  8. Plat AW, Rasouli N, Peleshok J, Sapin H, Wilding J. Change in Body Weight from Baseline with Tirzepatide: Sex Subgroup Analysis of the SURPASS Studies. Diabetes 2022;71 (supplement_1):720-P.
  9. Małecki MT, Batterham RL, Sattar N, Levine JA, Rodríguez Á, Bergman BK et al. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4. Diabetes Care. 2023;46(12):2292-2299.
  10. Garcia LE, Chao A, Mojdami D, Forrester T, Taylor R, Chigusta F et al. Body weight reduction with tirzepatide by sex: a subgroup analysis of the SURMOUNT clinical trials (abstract). EASD Annual Meeting [cited 2025-10-28]
  11. Ou Y, Cui Z, Lou S, Zhu C, Chen J, Zhou L et al. Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups. Front Pharmacol. 2024;15:1463657.
  12. Mounjaro (tirzepatide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-01-11, cited 2025-10-28]
  13. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]